innovative medicines business returning to growth, novartis ceo says
Published 3 years ago • 461 plays • Length 3:29Download video MP4
Download video MP3
Similar videos
-
0:45
novartis ceo: company set to become a pure play, innovative medicine business after sandoz spin off
-
6:12
novartis ceo: expect continued growth in 2023
-
3:04
novartis ceo: spinoffs will see us succeed as a pure-play innovative medicines company
-
3:29
novartis generated $40 billion in innovative medicine sales, says ceo
-
1:51
committed to growing over 4% through 2026, says novartis ceo
-
9:32
vasant narasimhan novartis ceo on transforming pharma industry
-
9:32
vasant narasimhan novartis ceo on transforming pharma industry
-
23:37
reimagining medicine with data & digital | novartis ceo at #vivatech19
-
11:50
novartis ‘focusing on high-end, innovative medicines,’ ceo says
-
4:54
novartis ceo: confident about continued sales growth for rest of year
-
4:43
novartis ceo: our leukemia drug scemblix is a potential $3 billion plus medicine
-
4:16
novartis ceo vas narasimhan: our medicines are starting to take market share and deliver on promises
-
5:20
'attractive' growth ahead for novo nordisk, ceo says
-
3:43
novartis ceo vas narasimhan on the latest research on a breast cancer drug
-
7:51
watch cnbc's full interview with novartis ceo vas narasimhan
-
0:54
novartis as a focused innovative medicines company
-
6:02
novartis ceo on the company's pledge to provide no-profit medicines to low-income countries
-
4:11
novartis ceo on esg: pandemic has been a reset for pharma's reputation
-
4:17
novartis ceo: we expect our six key drugs to grow ahead of analyst expectations
-
4:22
novartis ceo on new cancer therapy programs
-
5:53
novartis expects 'strong momentum' going into second half, says ceo vasant narasimhan
-
9:48
novartis ceo: growth drivers performing well, but product exclusivity losses creating headwinds